- Home
- APVO vs KTTA Comparison
APVO vs KTTA Comparison
Compare APVO & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- KTTA
- Stock Information
- Founded
- APVO 2016
- KTTA 2020
- Country
- APVO United States
- KTTA United States
- Employees
- APVO N/A
- KTTA N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- APVO Health Care
- KTTA Health Care
- Exchange
- APVO Nasdaq
- KTTA Nasdaq
- Market Cap
- APVO 4.9M
- KTTA 5.5M
- IPO Year
- APVO N/A
- KTTA 2021
- Fundamental
- Price
- APVO $1.78
- KTTA $0.81
- Analyst Decision
- APVO
- KTTA
- Analyst Count
- APVO 0
- KTTA 0
- Target Price
- APVO N/A
- KTTA N/A
- AVG Volume (30 Days)
- APVO 16.3M
- KTTA 93.8K
- Earning Date
- APVO 11-06-2025
- KTTA 11-12-2025
- Dividend Yield
- APVO N/A
- KTTA N/A
- EPS Growth
- APVO N/A
- KTTA N/A
- EPS
- APVO N/A
- KTTA N/A
- Revenue
- APVO N/A
- KTTA N/A
- Revenue This Year
- APVO N/A
- KTTA N/A
- Revenue Next Year
- APVO N/A
- KTTA N/A
- P/E Ratio
- APVO N/A
- KTTA N/A
- Revenue Growth
- APVO N/A
- KTTA N/A
- 52 Week Low
- APVO $1.32
- KTTA $0.65
- 52 Week High
- APVO $381.10
- KTTA $5.45
- Technical
- Relative Strength Index (RSI)
- APVO 53.33
- KTTA 61.44
- Support Level
- APVO $1.41
- KTTA $0.70
- Resistance Level
- APVO $1.49
- KTTA $0.84
- Average True Range (ATR)
- APVO 0.18
- KTTA 0.03
- MACD
- APVO 0.04
- KTTA 0.01
- Stochastic Oscillator
- APVO 35.04
- KTTA 81.57
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).